Fulcrum Therapeutics (NASDAQ:FULC) Upgraded to Overweight at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC) from a neutral rating to an overweight rating in a research note issued to investors on Thursday, MarketBeat Ratings reports. Cantor Fitzgerald currently has $10.00 price target on the stock. Cantor Fitzgerald also issued estimates for Fulcrum Therapeutics’ FY2025 earnings at ($1.21) EPS.

Separately, HC Wainwright restated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.50.

Fulcrum Therapeutics Trading Up 17.2%

NASDAQ:FULC opened at $6.60 on Thursday. The company has a market capitalization of $356.26 million, a P/E ratio of -21.29 and a beta of 2.29. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $10.13. The firm has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $3.77.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. Equities analysts forecast that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in FULC. Suvretta Capital Management LLC grew its position in shares of Fulcrum Therapeutics by 182.3% in the fourth quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock valued at $15,691,000 after purchasing an additional 2,155,675 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Fulcrum Therapeutics by 50.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company’s stock worth $14,100,000 after purchasing an additional 1,000,000 shares during the last quarter. Woodline Partners LP raised its stake in shares of Fulcrum Therapeutics by 110.3% in the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock valued at $6,629,000 after acquiring an additional 739,713 shares during the period. ADAR1 Capital Management LLC raised its position in Fulcrum Therapeutics by 150.0% in the first quarter. ADAR1 Capital Management LLC now owns 490,532 shares of the company’s stock valued at $1,413,000 after purchasing an additional 294,284 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Fulcrum Therapeutics by 176.8% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock worth $1,728,000 after buying an additional 234,810 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.